CIK 0001438533 · Large accelerated filer
Travere Therapeutics, Inc.
Sign in to watch- Ticker
- TVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- CA
- Entity type
- operating
- EIN
- 262383102
- Phone
- 888-969-7879
- Business address
- 3611 VALLEY CENTRE DR, SUITE 300, SAN DIEGO, CA, 92130
- Former names
- Retrophin, Inc., Desert Gateway, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $79,812,468
- in 11 filings, $79.8M under 10b5-1 plans
Net −$79,812,468. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Dube Eric M −$38.5M CHIEF EXECUTIVE OFFICER sold 60% of stake
- Heerma Peter −$17.9M EVP, CHIEF COMMERCIAL OFFICER sold 71% of stake
- ROTE WILLIAM E. −$13.1M Chief Research Officer sold 68% of stake
- Cline Christopher R. −$3.2M CHIEF FINANCIAL OFFICER sold 37% of stake
- Inrig Jula −$2.8M EVP, Head of R&D & CMO sold 31% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-02-04 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −1,635 | $32.14 | $53K | 111,336 |
| 2026-02-04 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale 10b5-1 | −110 | $32.90 | $4K | 111,226 |
| 2026-02-04 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −1,547 | $32.11 | $50K | 105,938 |
| 2026-02-04 | Inrig Jula CHIEF MEDICAL OFFICER | Sale 10b5-1 | −232 | $32.85 | $8K | 105,706 |
| 2026-02-04 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −2,485 | $32.07 | $80K | 105,720 |
| 2026-02-04 | REED ELIZABETH E Chief Legal Officer and GC | Sale 10b5-1 | −509 | $32.74 | $17K | 105,211 |
| 2026-02-03 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Sale | −7,242 | $32.12 | $233K | 112,971 |
| 2026-02-03 | Inrig Jula CHIEF MEDICAL OFFICER | Sale | −6,956 | $32.12 | $223K | 107,485 |
| 2026-02-03 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Sale | −4,333 | $32.12 | $139K | 49,080 |
| 2026-02-03 | Heerma Peter CHIEF COMMERCIAL OFFICER | Sale | −7,310 | $32.12 | $235K | 131,823 |
| 2026-02-03 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −66,452 | $32.06 | $2.1M | 466,521 |
| 2026-02-03 | Dube Eric M CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −33,635 | $32.70 | $1.1M | 432,886 |
| 2026-02-03 | ROTE WILLIAM E. Chief Research Officer | Sale 10b5-1 | −12,446 | $32.87 | $409K | 109,087 |
| 2026-02-03 | REED ELIZABETH E Chief Legal Officer and GC | Sale | −7,175 | $32.12 | $230K | 108,205 |
| 2026-01-31 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Grant or award | +28,130 | 120,213 | ||
| 2026-01-31 | Cline Christopher R. CHIEF FINANCIAL OFFICER | Grant or award · Employee stock option (right to buy) | +75,000 | 75,000 | ||
| 2026-01-31 | Inrig Jula CHIEF MEDICAL OFFICER | Grant or award | +28,130 | 114,441 | ||
| 2026-01-31 | Inrig Jula CHIEF MEDICAL OFFICER | Grant or award · Employee stock option (right to buy) | +75,000 | 75,000 | ||
| 2026-01-31 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Grant or award | +15,180 | 53,413 | ||
| 2026-01-31 | Calvin Sandra SVP, CHIEF ACCOUNTING OFFICER | Grant or award · Employee stock option (right to buy) | +20,160 | 20,160 |
Page 13 of 51 · 1,020 trades